Drs. Glick and Marder Reply

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The authors of the letter raise a number of interesting issues.

They expressed a concern that the study1 was biased toward quetiapine because of the open-label design and the use of a dose of quetiapine that was higher than the equivalent dose of haloperidol decanoate. We used an open-label design with blinded ratings in order to increase the external validity of the study.

J Clin Psychiatry 2006;67(3):497-498 [letter]